NASDAQ:RNXT

RenovoRx (RNXT) Stock Forecast, Price & News

$1.87

+0.01 (+0.54%)

(As of 05/31/2023 ET)

Compare

Today's Range: $1.71
▼
$2.09
50-Day Range: $1.85
▼
$3.90
52-Week Range: $1.50
▼
$5.75

Volume: 36,102 shs
Average Volume: 51,105 shs
Market Capitalization: $18.95 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

RenovoRx MarketRank™ Forecast

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.16% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.46
Based on 3 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.00) to ($0.80) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.45 out of 5 stars

Medical Sector

941st out of 1,006 stocks

Pharmaceutical Preparations Industry

468th out of 492 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for RenovoRx.

5.0

Short Interest

Percentage of Shares Shorted
0.16% of the float of RenovoRx has been sold short.
Short Interest Ratio / Days to Cover
RenovoRx has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in RenovoRx has recently decreased by 49.61%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
RenovoRx does not currently pay a dividend.
Dividend Growth
RenovoRx does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for RNXT.

2.5

News and Social Media Coverage

News Sentiment
RenovoRx has a news sentiment score of 0.46. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.78 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for RenovoRx this week, compared to 1 article on an average week.
MarketBeat Follows
3 people have added RenovoRx to their MarketBeat watchlist in the last 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, RenovoRx insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 9.02% of the stock of RenovoRx is held by insiders.
Percentage Held by Institutions
Only 13.56% of the stock of RenovoRx is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for RenovoRx are expected to grow in the coming year, from ($1.00) to ($0.80) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of RenovoRx is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of RenovoRx is -1.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
RenovoRx has a P/B Ratio of 5.84. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About RenovoRx (NASDAQ:RNXT) Stock

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.

Receive RNXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

RNXT Stock News Headlines

May 25, 2023 | finanznachrichten.de

RenovoRx, Inc.: RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer

May 25, 2023 | finance.yahoo.com

RenovoRx Announces Late-Breaking Oral Presentation at 2023 ESMO World Congress on Gastrointestinal Cancer

June 1, 2023 | Vantage Point (Ad)

We Called (ARWR) In Advance, Which Stocks Are Next?

Nearly 56% gains in 30 days! This bullish trend reversal was not only forecasted by A.I., but we called it 1 – 3 days in advance. If you have any money invested in the markets…even just your retirement, you’ll want to see this. Plus, it’s FREE - the training is only an hour & LIVE.

May 24, 2023 | finance.yahoo.com

RenovoRx to Present at the LD Micro Invitational XIII Conference

May 18, 2023 | markets.businessinsider.com

Maxim Group Keeps Their Buy Rating on RenovoRx (RNXT)

May 15, 2023 | finance.yahoo.com

RenovoRx Reports First Quarter 2023 Financial Results and Operational Highlights

May 1, 2023 | finance.yahoo.com

RenovoRx Sponsors Pancreatic Cancer Action Network’s PurpleStride® Event

April 28, 2023 | finance.yahoo.com

RenovoRx to Participate in the Aegis Capital Virtual Conference on May 3, 2023

June 1, 2023 | Behind the Markets (Ad)

Laser breakthrough could send stock soaring 2,467%

Laser breakthrough could send stock soaring 2,476% Whenever the military develops a breakthrough technology, timely investors could see groundbreaking returns. General Dynamics returned 8,990%... Boeing soared 4,238%... L3Harris shot up 1,628%...

April 27, 2023 | finance.yahoo.com

RenovoRx Appoints Former Chief Medical Officer of Schering-Plough, Robert J. Spiegel, MD, FACP, to Board of Directors

April 14, 2023 | finance.yahoo.com

RenovoRx Presenting Phase III Clinical Trial Interim Analysis Data of the TIGeR-PaC Study at American Association for Cancer Research Annual Meeting Underway in Orlando, Florida

April 14, 2023 | americanbankingnews.com

Comparing RenovoRx (NASDAQ:RNXT) & Inozyme Pharma (NASDAQ:INZY)

April 11, 2023 | finance.yahoo.com

RenovoRx Appoints Leesa Gentry as Senior Vice President of Clinical Operations

March 30, 2023 | markets.businessinsider.com

RenovoRx Reports Positive Data From Phase III Trial Interim Analysis Of RenovoGem Therapy

March 30, 2023 | finance.yahoo.com

RenovoRx Announces Positive New Data from Phase III Clinical Trial Interim Analysis: 60% Survival Benefit and Fewer Side Effects than Systemic Chemotherapy

March 30, 2023 | finance.yahoo.com

RenovoRx, Inc. Announces $5 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules

March 8, 2023 | finance.yahoo.com

RenovoRx's Targeted Prostate Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care

March 8, 2023 | finance.yahoo.com

RenovoRx Phase III Open Label TIGeR-PaC Interim Analysis Shows Promising Data That Support Continued Clinical Investigation of RenovoGemTM as a Treatment Option for Locally Advanced Pancreatic Cancer

March 8, 2023 | finance.yahoo.com

RenovoRx's Targeted Pancreatic Cancer Treatment Shows Positive Trend In Median Overall Survival Versus Standard Care

March 6, 2023 | benzinga.com

RenovoRx, Inc. Full-year 2022 Results Provide Clues Supporting A Near-Term Catalyst-Fueled Breakout ($RNXT)

March 3, 2023 | finance.yahoo.com

RenovoRX's Latest Innovative Technology Creates New Hope For Chemotherapy Patients

March 2, 2023 | finance.yahoo.com

RenovoRx Reports Full Year 2022 Financial Results and Achievement of Important Phase III Clinical Study Milestone

March 1, 2023 | finance.yahoo.com

RenovoRx to Present at the 35th Annual Roth Conference on March 13, 2023

January 25, 2023 | finance.yahoo.com

RenovoRx to Present at the Sequire Biotechnology Virtual Conference on February 2, 2023

January 18, 2023 | finance.yahoo.com

RenovoRx Announces Initial Results in Pharmacokinetic (PK) Substudy: Data on RenovoGem™ Supports Potential for RenovoTAMP® Therapy Platform to Increase Local Gemcitabine (Chemotherapy) Delivery and Decrease Side Effects of Pancreatic Cancer Treatment

January 11, 2023 | finance.yahoo.com

Here's Why RenovoRx (NASDAQ:RNXT) Must Use Its Cash Wisely

January 5, 2023 | finance.yahoo.com

RenovoRx Strengthens Intellectual Property (IP) Portfolio with Eighth US Patent

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive RNXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for RenovoRx and its competitors with MarketBeat's FREE daily newsletter.

RNXT Company Calendar

Last Earnings: 3/02/2023
Today: 5/31/2023
Next Earnings (Estimated): 8/21/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:RNXT
CUSIP: N/A
CIK: 1574094
Web: www.renovorx.com
Phone: 650-284-4433
Fax: 650-397-4433
Employees: 10
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): ($1.12)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-9,890,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -146.73%
Return on Assets: -125.70%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.31
Quick Ratio: 3.31

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.32 per share
Price / Book: 5.84

Miscellaneous

Outstanding Shares: 10,130,000
Free Float: 9,218,000
Market Cap: $18.94 million
Optionable: Not Optionable
Beta: -0.01

Key Executives

Dr. Ramtin Agah M.D. (Age 55)
Founder, Chairman of Board & Chief Medical Officer
Comp: $216.67k

Mr. Shaun R. Bagai (Age 44)
CEO & Director
Comp: $482.81k

Mr. James M. Ahlers (Age 58)
Chief Financial Officer

Ms. Angela Gill Nelms
Chief Operating Officer

Mr. Ronald B. Kocak CPA
VP & Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

RNXT Stock - Frequently Asked Questions

How have RNXT shares performed in 2023?: RenovoRx's stock was trading at $2.35 on January 1st, 2023. Since then, RNXT stock has decreased by 20.4% and is now trading at $1.87.
View the best growth stocks for 2023 here.
Are investors shorting RenovoRx?: RenovoRx saw a drop in short interest in May. As of May 15th, there was short interest totaling 13,000 shares, a drop of 49.6% from the April 30th total of 25,800 shares. Based on an average trading volume of 52,300 shares, the short-interest ratio is presently 0.2 days. Currently, 0.2% of the shares of the company are short sold.
View RenovoRx's Short Interest.
When is RenovoRx's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our RNXT earnings forecast.
How were RenovoRx's earnings last quarter?: RenovoRx, Inc. (NASDAQ:RNXT) issued its earnings results on Thursday, March, 2nd. The company reported ($0.23) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.26) by $0.03.
When did RenovoRx IPO?: (RNXT) raised $18 million in an initial public offering (IPO) on Thursday, August 26th 2021. The company issued 1,800,000 shares at $9.00-$11.00 per share. Roth Capital Partners and Maxim Group LLC served as the underwriters for the IPO.

What is RenovoRx's stock symbol?: RenovoRx trades on the NASDAQ under the ticker symbol "RNXT."
Who are RenovoRx's major shareholders?: RenovoRx's stock is owned by many different institutional and retail investors. Top institutional investors include Armistice Capital LLC (10.80%) and Geode Capital Management LLC (0.46%). Insiders that own company stock include Ramtin Agah and Shaun Bagai.
View institutional ownership trends.
How do I buy shares of RenovoRx?: Shares of RNXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is RenovoRx's stock price today?: One share of RNXT stock can currently be purchased for approximately $1.87.
How much money does RenovoRx make?: RenovoRx (NASDAQ:RNXT) has a market capitalization of $18.94 million. The company earns $-9,890,000.00 in net income (profit) each year or ($1.12) on an earnings per share basis.
How can I contact RenovoRx?: RenovoRx's mailing address is 333 W. SANTA CLARA STREET SUITE 900, SAN JOSE CA, 95110. The official website for the company is www.renovorx.com. The company can be reached via phone at 650-284-4433, via email at renovorx@kcsa.com, or via fax at 650-397-4433.

This page (NASDAQ:RNXT) was last updated on 6/1/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

RenovoRx (RNXT) Stock Forecast, Price & News

RenovoRx MarketRank™ Forecast

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About RenovoRx (NASDAQ:RNXT) Stock

RNXT Stock News Headlines

RNXT Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

RNXT Stock - Frequently Asked Questions

Overall MarketRank^™